Cynata Therapeutics (STU:51S) Capital Expenditure : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cynata Therapeutics Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Cynata Therapeutics's cash flow for capital expenditures for the six months ended in Dec. 2023 was €0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.

Cynata Therapeutics Capital Expenditure Historical Data

The historical data trend for Cynata Therapeutics's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynata Therapeutics Capital Expenditure Chart

Cynata Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Capital Expenditure

Get a 7-Day Free Trial

Cynata Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Capital Expenditure	Get a 7-Day Free Trial															-	-	-	-	-

Cynata Therapeutics Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Cynata Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (STU:51S) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

CYP:Australia

Address

100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121

Website

https://www.cynata.com

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics Headlines

No Headlines